BP-LOWERING treatment with perindopril decreases the likelihood of major vascular events and stroke in CKD patients with cerebrovascular disease.

BARCELONA--Pro-inflammatory cytokines are a marker for increased cardiovascular and overall mortality in dialysis patients, new research demonstrates.

ANAHEIM, Calif.—Nephrolithiasis may be associated with a modest but significantly elevated risk of heart disease, according to a new study presented here at American Urological Association annual meeting.

PROLONGED ACE inhibitor treatment can reverse left ventricular hypertrophy (LVH) in renal transplant recipients receiving cyclosporine-based immunosuppression, according to researchers.

CHICAGO—Diabetics with CKD whose anemia is untreated have twice the overall risk of CVD-related hospitalizations, according to data reported at the 67th Scientific Sessions of the American Diabetes Association.

Survival after renal transplantation is significantly lower in allograft recipients with known coronary artery disease, data show.

Serum levels of fetuin-A predictor of all-cause, cardiovascular, and non-cardiovascular mortality in dialysis patients, a Dutch study found.

SEATTLE—Percutaneous transluminal angioplasty (PTA) safely treats infragenicular arterial disease and helps to preserve limbs, according to a study presented here at the Society of Interventional Radiology annual meeting.

DENVER—Hemodialysis (HD)-dependent chronic renal failure (CRF) patients do not have higher mortality following coronary artery bypass grafting (CABG) than non-HD dependent CRF patients.

The renin-angiotensin-aldosterone system (RAAS) is a well-known regulator of BP, and angiotensin II (AII) plays the primary role in constricting the postglomerular arterioles. This increases both the glomerular hydraulic pressure and the ultrafiltration of plasma proteinseffects that may con- tribute to chronic renal damage. AII may stimulate renal cell growth, inflammation, and fibrosis.